ALXO ALX Oncology Holdings Inc.: Multiplikator nilai perusahaan marang pendapatan

High dependence on a single CD47 blocking method creates significant risks for ALX Oncology Holdings (ALXO). This EV/Sales chart helps identify areas of market overvaluation for the asset, where 0.00 serves as the base parameter value. US-based research and a next-generation platform support the business's stability. A competitive advantage is provided by the drug evorpacept, which effectively destroys tumors while preserving erythrocytes.
alxoncology.com - rincian analitis lan metrik utama (ALXO)

This multiple compares the total enterprise value of ALX Oncology Holdings (ALXO) with its annual revenue, excluding the impact of leverage to determine the actual market value of the assets. By analyzing the EV/Sales valuation ratio, an investor determines the extent of priced-in expectations regarding the success of CD47 immunotherapy, where a high valuation reflects the potential for breakthrough clinical trials by ALX Oncology Holdings (ALXO) in the fight against cancer.